Bristol Myers Squibb (NYSE:BMY) Stock Gets Price Target Trim from Morgan Stanley

Bristol Myers Squibb (NYSE:BMY) had its price objective trimmed by Morgan Stanley from $41.00 to $40.00 in a research report report published on Friday,Benzinga reports. They currently have an underweight rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on BMY. TD Cowen started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating for the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 13th. Guggenheim reiterated a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Citigroup reissued a “neutral” rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Finally, Leerink Partners downgraded Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $73.00 to $59.00 in a research note on Monday, October 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $65.46.

Bristol Myers Squibb Stock Down 0.0%

Shares of Bristol Myers Squibb stock opened at $62.46 on Friday. The company has a 50-day simple moving average of $62.80 and a two-hundred day simple moving average of $59.94. The stock has a market capitalization of $127.67 billion, a PE ratio of 13.85, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb has a 52-week low of $45.20 and a 52-week high of $68.64. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. The company had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb’s revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.63 earnings per share. On average, analysts anticipate that Bristol Myers Squibb will post 6.40 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb’s payout ratio is currently 55.88%.

Insider Buying and Selling

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.05% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bristol Myers Squibb

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $27,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $32,000. William Mack & Associates Inc. purchased a new position in shares of Bristol Myers Squibb during the third quarter valued at approximately $35,000. Groupe la Francaise grew its position in shares of Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 501 shares in the last quarter. Finally, Kilter Group LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter worth $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.